Expanded Access Protocol Using HBOC-201
- Conditions
- Anemia
- Registration Number
- NCT02684474
- Lead Sponsor
- Johns Hopkins University
- Brief Summary
The purpose of this protocol is to provide treatment with HBOC-201 to patients with life-threatening anemia for whom allogeneic blood transfusion is not an option. HBOC 201 \[hemoglobin glutamer - 250 (bovine)\] has been previously studied as an alternative to blood transfusions in severely anemic patients needing a way to enhance tissue oxygenation. HBOC-201 is purified, cross-linked and polymerized acellular bovine hemoglobin in a modified lactated Ringer's solution, and does not require blood compatibility.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
-
Patients ≥ 18 years of age
-
Critically ill patients with hemoglobin ≤ 6 g/dL (or 7-8 g/dL with significant active bleeding), and physiologic evidence of critical ischemia, for example: elevated troponins, altered mental status, acute renal failure, lactic acidosis or evidence of central nervous system acute deficits
-
Patients or their Legally Authorized Representative who are able and willing to provide informed consent
-
Blood is not an option due to:
- refusal of transfusion
- lack of compatible red blood cells
-
Patients with known hypersensitivity or allergy to beef products
-
Patients with pre-existing uncontrolled hypertension, heart failure, renal failure, circulatory hypervolemia or systemic mastocytosis*
-
Patients who are eligible for blood transfusions
-
Patients who are > 80 years old*
- on a case by case and quality of life determination
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The Johns Hopkins Hospital
🇺🇸Baltimore, Maryland, United States